Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Senti Biosciences Inc SNTI

Healthcare Biotechnology
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy... see more

Recent & Breaking News (NDAQ:SNTI)

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

GlobeNewswire March 14, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Business Wire February 21, 2023

Senti Biosciences Announces New Employment Inducement Grants

GlobeNewswire February 3, 2023

Senti Bio to Present at the SVB Securities Global Biopharma Conference

GlobeNewswire February 1, 2023

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

GlobeNewswire January 27, 2023

Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2022

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

GlobeNewswire December 11, 2022

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

GlobeNewswire November 23, 2022

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

GlobeNewswire November 10, 2022

Senti Bio to Present Preclinical Data for SENTI-202 at the 2022 ASH Annual Meeting

GlobeNewswire November 3, 2022

Senti Bio Announces New Employment Inducement Grants

GlobeNewswire October 28, 2022

Senti Bio to Present Preclinical Data on Cancer-Killing Allogeneic CAR-NK Cells at SITC Annual Meeting

GlobeNewswire October 5, 2022

Senti Bio to Participate in Chardan's 6th Annual Genetic Medicines Conference

GlobeNewswire September 20, 2022

Senti Bio to Present at Morgan Stanley 20th Annual Global Healthcare Conference

GlobeNewswire September 6, 2022

Chardan Announces Launch of ChEF (Chardan Equity Facility)

PR Newswire September 1, 2022

Senti Biosciences Announces New Employment Inducement Grants

GlobeNewswire August 19, 2022

Senti Bio Reports Second Quarter Financial Results and Business Updates

GlobeNewswire August 15, 2022

Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits

GlobeNewswire June 9, 2022

 Dynamics Special Purpose Corp. Announces Closing of $230 Million Initial Public Offering Including Full Exercise of Underwriters' Over-Allotment Option

Business Wire May 28, 2021

Dynamics Special Purpose Corp. Announces Pricing of $200 Million Initial Public Offering

Business Wire May 25, 2021